Alk-Abello AS

4AJ0

Company Profile

  • Business description

    Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.

  • Contact

    Boge Alle 6-8
    HorsholmDK-2970
    DNK

    T: +45 45747576

    E: [email protected]

    https://www.alk.net

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    2,759

Stocks News & Analysis

stocks

Two ASX shares get takeover bids

Our take on the two bids.
stocks

Anthropic and OpenAI face commodification threats. Here’s what to watch for

Frontier AI labs face a three-pronged set of challenges.
stocks

Berkshire Hathaway: Abel pushes into new territory with Bending Spoons investment

We think it is a sign that the firm is finally moving out of its comfort zone to find places to put capital to work.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,941.4034.30-0.38%
CAC 407,868.0588.65-1.11%
DAX 4025,319.77302.84-1.18%
Dow JONES (US)51,966.0336.38-0.07%
FTSE 10010,764.69117.21-1.08%
HKSE23,935.16251.67-1.04%
NASDAQ26,430.89290.851.11%
Nikkei 22564,031.99884.71-1.36%
NZX 50 Index13,631.6920.38-0.15%
S&P 5007,690.7331.290.41%
S&P/ASX 2008,813.8031.90-0.36%
SSE Composite Index3,719.3311.59-0.31%

Market Movers